ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Endonovo Therapeutics Inc (PK)

Endonovo Therapeutics Inc (PK) (ENDV)

0.0008
0.0001
(14.29%)
Closed 05 January 8:00AM

Professional-Grade Tools, for Individual Investors.

Key stats and details

Current Price
0.0008
Bid
0.0001
Offer
0.05
Volume
16,171,250
0.0007 Day's Range 0.0008
0.00035 52 Week Range 0.0134
Market Cap
Previous Close
0.0007
Open
0.0007
Last Trade Time
Financial Volume
US$ 12,353
VWAP
0.000764
Average Volume (3m)
10,435,016
Shares Outstanding
396,830,000
Dividend Yield
-
PE Ratio
0.00
Earnings Per Share (EPS)
0.02
Revenue
140k
Net Profit
6.93M

About Endonovo Therapeutics Inc (PK)

Endonovo Therapeutics (OTCQB: ENDV) is a commercial stage developer of non-invasive medical devices designed to deliver its proprietary Electroceutical Therapy for the treatment of inflammatory conditions, cardiovascular diseases and central nervous system disorders. Endonovo's Electroceutical Thera... Endonovo Therapeutics (OTCQB: ENDV) is a commercial stage developer of non-invasive medical devices designed to deliver its proprietary Electroceutical Therapy for the treatment of inflammatory conditions, cardiovascular diseases and central nervous system disorders. Endonovo's Electroceutical Therapy is FDA-Cleared for the palliative treatment of pain and post-surgical edema (swelling) and CE Marked for the promotion of wound healing and the palliative treatment of pain and post-surgical edema. Endonovo's Electroceutical Therapy has CMS National Coverage for the treatment of chronic wounds. The Company's current pipeline of clinical-stage Electroceutical Therapies targets cardiovascular diseases and central nervous system disorders, including ischemic heart disease, acute concussions, post-concussion syndrome, traumatic brain injury (TBI) and multiple sclerosis. Show more

Sector
Electromedical Apparatus
Industry
Electromedical Apparatus
Headquarters
Wilmington, Delaware, USA
Founded
-
Endonovo Therapeutics Inc (PK) is listed in the Electromedical Apparatus sector of the OTCMarkets with ticker ENDV. The last closing price for Endonovo Therapeutics (PK) was US$0. Over the last year, Endonovo Therapeutics (PK) shares have traded in a share price range of US$ 0.00035 to US$ 0.0134.

Endonovo Therapeutics (PK) currently has 396,830,000 shares in issue. The market capitalisation of Endonovo Therapeutics (PK) is US$277,781 . Endonovo Therapeutics (PK) has a price to earnings ratio (PE ratio) of 0.00.

ENDV Latest News

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.00041000.00040.00090.00035393242100.00068488CS
43.5E-54.575163398690.0007650.000950.00035213429720.0006277CS
12-0.0002-200.0010.00160.00035104350160.00065969CS
26-0.0001-11.11111111110.00090.00190.0003555919270.00070285CS
52-0.0061-88.40579710140.00690.01340.0003535740680.00102391CS
156-0.019-95.95959595960.01980.0280.0003513264840.00264019CS
260-1.2392-99.9354838711.243.90.000358803610.01365513CS

ENDV - Frequently Asked Questions (FAQ)

What is the current Endonovo Therapeutics (PK) share price?
The current share price of Endonovo Therapeutics (PK) is US$ 0.0008
How many Endonovo Therapeutics (PK) shares are in issue?
Endonovo Therapeutics (PK) has 396,830,000 shares in issue
What is the market cap of Endonovo Therapeutics (PK)?
The market capitalisation of Endonovo Therapeutics (PK) is USD 277.78k
What is the 1 year trading range for Endonovo Therapeutics (PK) share price?
Endonovo Therapeutics (PK) has traded in the range of US$ 0.00035 to US$ 0.0134 during the past year
What is the cash to sales ratio of Endonovo Therapeutics (PK)?
The cash to sales ratio of Endonovo Therapeutics (PK) is 0
What is the reporting currency for Endonovo Therapeutics (PK)?
Endonovo Therapeutics (PK) reports financial results in USD
What is the latest annual turnover for Endonovo Therapeutics (PK)?
The latest annual turnover of Endonovo Therapeutics (PK) is USD 140k
What is the latest annual profit for Endonovo Therapeutics (PK)?
The latest annual profit of Endonovo Therapeutics (PK) is USD 6.93M
What is the registered address of Endonovo Therapeutics (PK)?
The registered address for Endonovo Therapeutics (PK) is 251 LITTLE FALLS DRIVE, WILMINGTON, DELAWARE, 19808
What is the Endonovo Therapeutics (PK) website address?
The website address for Endonovo Therapeutics (PK) is www.endonovo.com
Which industry sector does Endonovo Therapeutics (PK) operate in?
Endonovo Therapeutics (PK) operates in the ELECTROMEDICAL APPARATUS sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
EGIOQEdgio Inc (CE)
US$ 0.01
(999,900.00%)
584
AAGRAfrican Agriculture Holdings Inc (CE)
US$ 0.008
(799,900.00%)
477
THCBFTHC Biomed International Limited (CE)
US$ 0.001
(99,900.00%)
100
AEORFAEON REIT Investment Corporation (PK)
US$ 796.08
(26,436.00%)
1
EFTReFFECTOR Therapeutics Inc (CE)
US$ 0.0002
(19,900.00%)
225
UFABQUnique Fabricating Inc (CE)
US$ 0.000001
(-99.98%)
102.53k
VICFFVice Health and Wellness Inc (CE)
US$ 0.000001
(-99.97%)
996
SAFSSafer Shot Inc (CE)
US$ 0.000001
(-99.93%)
2.54M
ERFBERF Wireless Inc (CE)
US$ 0.0001
(-99.89%)
99.77k
ARVLFArrival (CE)
US$ 0.0002
(-99.60%)
42.86k
AITXArtificial Intelligence Technology Solutions Inc (PK)
US$ 0.0038
(52.00%)
608.97M
HMBLHUMBL Inc (PK)
US$ 0.0009
(0.00%)
546.25M
PHILPHI Group Inc (PK)
US$ 0.0003
(0.00%)
501.07M
CBIACanopus Biopharma Inc (PK)
US$ 0.0002
(100.00%)
281.95M
RDARRaadr Inc (PK)
US$ 0.00125
(-10.71%)
169.44M

ENDV Discussion

View Posts
Alley-oop Alley-oop 1 hour ago
The record date is crucial for determining eligibility, but as of now, no official record date for the SofPulse dividend has been announced in public statements.
๐Ÿ‘๏ธ0
Biotech_Tradez Biotech_Tradez 5 hours ago
They will fund all those things with their overdrawn bank account and zero sales for last quarter! LOL!

Give us a break.
๐Ÿ‘๏ธ0
GetSeriousOK GetSeriousOK 9 hours ago
Thanks! one last question:

How do they determine which ENDV shareholders get the stock dividend? Is it "shareholders as of a certain date," and if so, what is that date?
๐Ÿ‘๏ธ0
Alley-oop Alley-oop 21 hours ago
Summary of Endonovoโ€™s Restructured Business Model

Focus on Digital Health and AI Integration:

Endonovo Therapeutics (ENDV) is reorganizing to develop an integrated AI-powered digital healthcare and wellness platform.
The platform aims to enhance patient engagement, streamline access for healthcare providers, and expand retail sales of wellness and medical products.

Expansion into the Wellness Market:

ENDV is entering the $4.3 trillion global wellness market (projected to reach $7 trillion by 2025) with a focus on e-commerce.
Its platform will feature AI-integrated e-commerce for wellness products, including the companyโ€™s Pulsed Electro Magnetic Field (PEMF) multi-coil technology.

Market Potential and AI Differentiation:

The digital health market, valued at $375.99 billion in 2022, is projected to grow to $1.965 trillion by 2030 at a CAGR of 23.3%.
ENDV's AI integration will provide advanced analytics, predictive marketing, and enhanced customer engagement, setting its platform apart from competitors.

Strategic Goals:

Transform patient care across medical and wellness industries.
Utilize AI for better insights into customer behavior, targeted marketing, and efficient customer support.

Company Structure:

Digital Health and Wellness Division: Focused on the AI-powered platform and e-commerce marketplace.
Legacy Division: Developer of non-invasive wearable Electroceutical® devices for general wellness.
๐Ÿ‘๏ธ0
Biotech_Tradez Biotech_Tradez 22 hours ago
LOL! Repeating the same BS as the last pump and dumper!

This company's contraption doesn't work like they said it did. It lacks real studies. All their scientists left to start their own competitor company as Craig previously posted. They originally were going to acquire this technology for $28 million, then sued and bought it for $4.5 million which is probably what it was worth and proceeded to destroy all its value by proving they couldn't sell the product, dropping the concussion studies, and suing their competitors and failing. So, how on God's green earth is the valuation supposed to suddenly increase over 10x what they paid for it? I guess they plan to sprinkle fairy dust on it.

It has been a year and they still have not gotten it done, guess why? Nobody will issue a valuation for them because they could get sued. Nobody is going to finance it to go onto NASDAQ. It takes around $10 million to get on. Lastly, the debt holders will be the fist to dump the shares in order to get their money, which they will convert to freely traded shares long before any retail investor can. This is another one of the CEO's scams to keep milking money out of investors.
๐Ÿ‘๏ธ0
Alley-oop Alley-oop 23 hours ago
1. Will SofPulse Be Public or Private?

Initial Status: SofPulse, Inc. will remain private at the time of acquisition completion.

Future Plans:
SofPulse intends to meet the regulatory requirements for a NASDAQ listing, suggesting that it plans to become a publicly traded company in the near future.

2. If SofPulse Is Going Public, Will They Have an IPO or Buy a Shell?

Likely Approach:
Based on the announcement, SofPulse plans to go public through a direct listing or IPO on NASDAQ. This process involves filing with the SEC and meeting NASDAQ's listing criteria.
There is no indication of using a reverse merger with a shell company, though it could remain an option if a direct listing proves challenging.

3. Would ENDV Shareholders Get Restricted SofPulse Shares? If Restricted, When/How Can They Sell?

Restricted Shares:
The shares issued to ENDV shareholders will likely be restricted, meaning they cannot be sold immediately upon receipt.

Restriction Period: Restricted shares typically have a lock-up period (commonly 6โ€“12 months) during which they cannot be traded.

Selling Process:
After the restriction period expires, shareholders may need to comply with Rule 144 of the Securities Act to sell their shares, including filing appropriate documentation.

4. If ENDV Shareholders Get a Dividend... Where Will the New SofPulse Entity Get $40 Million?

Source of Funds:
Stock, Not Cash: The $40 million dividend will be issued in SofPulse restricted stock, not cash. SofPulse, Inc. is not required to have $40 million in cash on hand to fulfill this
commitment.

Capital Raise: SofPulse plans to raise up to $500,000 in a pre-money valuation of $10 million. Future funding rounds or operational revenue may support the valuation and company growth.

Valuation-Linked Payment:
If the updated third-party valuation exceeds $50 million, the additional amount will be paid through a senior note convertible into NASDAQ-listed marketable securities.
๐Ÿ‘๏ธ0
GetSeriousOK GetSeriousOK 1 day ago
Can you explain how this distribution to ENDV shareholders would work?

Will SofPulse be public or private?

If SofPulse is going public, will they have an IPO or will they buy a shell?

Would ENDV shareholders get restricted SofPulse shares? If restricted, when/how can they sell?

If ENDV shareholders get a dividend... 80% of $50 million is $40 million. Where will this new SofPulse entity get $40 million?

Thanks!
๐Ÿ‘๏ธ0
Alley-oop Alley-oop 1 day ago
$ENDV Benefits for Common Shareholders from the SofPulse Transaction
Stock Dividend or Alternative Mechanism:

As part of the agreement, 80% of the $50 million in restricted stock (priced at $5.00 per share) from SofPulse, Inc. will be issued to Endonovoโ€™s (ENDV) shareholders. This provides a direct benefit to common shareholders, effectively transferring a portion of the value from the sale to them.
Potential Uplisting to NASDAQ:

SofPulse, Inc. has committed to fulfilling regulatory requirements for a NASDAQ listing. This uplisting could significantly increase the liquidity and perceived value of the issued shares, benefiting shareholders holding the restricted stock.
Additional Valuation-Based Payments:

A third-party valuation may determine the assets' value to be higher than $50 million (up to $100 million). The difference will be issued to ENDV in the form of a senior note, which could further increase the benefits distributed to shareholders.
Strengthened Future Prospects:

SofPulseโ€™s plans for substantial growth, including:
Expanding Federal Supply Schedule contracts with the VA and Department of Defense.
Developing international markets.
Targeting annual revenues of $100 million by 2025.
Shareholders may benefit if the company achieves these projections and their issued shares gain value over time.
ENDV's Continued Operations:

ENDV will retain its telehealth division and mergers/acquisitions division, providing shareholders with additional growth opportunities in other sectors.
Capital Raise and Strategic Expansion:

SofPulseโ€™s $500,000 capital raise at a pre-money valuation of $10 million may position the company for sustained growth, indirectly supporting shareholder value.
๐Ÿ‘๏ธ0
Alley-oop Alley-oop 1 day ago
$ENDV SofPulse, a FDA Cleared medical device company specializing in non-invasive microcurrent therapy, has undergone several valuations in recent years:

2018 Valuation: A third-party assessment valued SofPulse's intellectual property and assets at $75 million.

2023 Agreement: Endonovo Therapeutics, the parent company, entered into a definitive agreement to sell SofPulse's business and medical intellectual property to SofPulse, Inc. for a minimum of $50 million. The final purchase price is subject to an updated valuation by a qualified third party, with estimates ranging between $50 million to $100 million.
๐Ÿ‘๏ธ0
Biotech_Tradez Biotech_Tradez 1 day ago
Another Pump & Dump Scammer shows up! How original!
๐Ÿ‘๏ธ0
GetSeriousOK GetSeriousOK 1 day ago
Where is the $50 million?

https://www.otcmarkets.com/stock/ENDV/news/Endonovo-Signs-Definitive-Agreement-to-Sell-SofPulse-Brand-Business-and-IP-to-SofPulse-Inc-for-a-minimum-of-50-Million?id=423534

Is ANY part of that $50 million going to be in cash? If so, when will it appear on the balance sheet?

If it's all going to be in SofPulse stock...... then this is a scam like the LLBO scam, where LLBO spun off their IP to a company called Cyrcadia. LLBO shareholders were left holding a bag of nothing.

Cyrcadia raised some money but when Cyrcadia could no longer convince anyone to invest, it all disappeared.
๐Ÿ‘๏ธ0
Craig305 Craig305 1 day ago
There is a reason for the SP being this low.
Just scroll down and read the posts.
Major dilution going to be happening due to lawsuit settlement.
Look at the dilution that happened just a few weeks ago. That is a drop in the bucket compared to what is coming.
๐Ÿ‘๏ธ0
Alley-oop Alley-oop 1 day ago
Low OS. I have never seen this low OS in OTC at sub penny level.
๐Ÿ‘๏ธ0
Alley-oop Alley-oop 1 day ago
Pre market volume
๐Ÿ‘๏ธ0
brojazzy brojazzy 2 days ago
Piece of shit SCAM!
👍 2
Alley-oop Alley-oop 2 days ago
$ENDV Development of Endonovo Digital Wellness Market Place


The company looks to expand its operations and enter the Wellness Industry to market wellness and medical products. In 2024, the wellness market is valued as a $4.3 trillion dollar industry that is expected to expand to $7 trillion dollars by 2025, as reported by statisa.com. ENDVโ€™s wellness platform will feature wellness and medical products and services, including its non-medical Pulsed Electro Magnetic Field (PEMF) multi-coil technology, on an AI integrated e-commerce platform/marketplace with distribution through network platforms.
👎️ 3
Biotech_Tradez Biotech_Tradez 2 weeks ago
New Target Price is $0.0001 Par Value

Given the last closing price of $0.0004 conversions will be taking place at a 50% discount which is $0.0002 which will drive down the stock price to that value over time. The exact timing is unknown and depends on the rate of selling on behalf of Trillium Partners. A reverse stock split is also on the horizon because they don't have enough authorized shares to cover even half of the amount that is going to be converted into freely traded stock at near par value.

This company's stock is valued at essentially ZERO due to the amount of debt that the company is holding. I don't believe they can sell all that stock to cover the debt and this is heading to a bankruptcy court. I believe Collier is on the hook for some money based on the documents filed a few years ago. My take is that he clears the debt he is a guarantor to before he throws this into bankruptcy. Their spin-out is not working because 1.) Ira cannot raise money based on a bloated valuation and 2.) Collier proved that the pain management device has no lucrative commercial viability.

They bought these assets for $4.5 million several years ago and since then have only tanked the valuation because they abandoned all the potentially lucrative applications of the technology such as the treatment of brain injury and they proved that their pain management device was not commercially viable. Simply put, acquiring this company at a $75 million valuation would produce a company who's only "asset" would be goodwill created by the bloated acquisition price.
👍 1
Craig305 Craig305 2 weeks ago
In just 1 week, the unrestricted share count increased 27%. 😯
273.2M to 347.5M
๐Ÿ‘๏ธ0
Craig305 Craig305 2 weeks ago
It appears to me the selling of those shares has commenced. This stock is doomed. Even trying to flip it at this point is not worthwhile. Trillium will sell/dump into any potential rally. 
💯 1
Biotech_Tradez Biotech_Tradez 2 weeks ago
It means a R/S and/or increase in Authorized shares is coming.

This notice is also very late, a month late. Very likely we already had a conversion at $0.00025-$0.0003
๐Ÿ‘๏ธ0
Craig305 Craig305 2 weeks ago
If those shares are issued at a SP of .0004, that would equate to 7 Billion shares. 😯. 
The A/S is only 2.5B at the current time. 
Wonder if all this volume and current Twitter pumping is trying to increase the SP so that the shares are not issued so cheaply. 😄
๐Ÿ‘๏ธ0
Biotech_Tradez Biotech_Tradez 3 weeks ago
BUYER BEWARE: $2.9 Million in debt to be converted at a 50% discount.

ENDV just lost a lawsuit and filed the following today:

On November 14, 2024, in a case entitled Trillium Partners, L.P. (โ€œTrilliumโ€) v Endonovo Therapeutics, Inc. (the โ€œCompanyโ€) in the Circuit Court for the 17th Judicial Circuit in and for Broward County Florida (Case No CACE24009960), the court issued an order (the โ€œOrderโ€) approving a settlement of $2,896,956.15 of the Companyโ€™s outstanding debt in exchange for the issuance of shares at a 50% discount to market under Section 3(a)(10) of the Securities Act of 1933, as amended. The shares, when issued pursuant to the Order, will be free of any restriction and be marketable securities. As a result of the Order, the Companyโ€™s outstanding indebtedness was reduced from approximately $2,896,956.15. The sale of shares under the Order, which has not yet commenced, may have a depressive affect on the market for the Companyโ€™s shares.
๐Ÿ‘๏ธ0
Demogod1 Demogod1 3 weeks ago
He's a scammer who works as a flooring salesman at his day job & literally every single ticker he's tried to pump he's had inside ties with. He's lied to & led his dumbass followers to financial ruin (CBIH, KYNC, ENDV, ASTA, & many more). He - like the tickers he pushes - pure garbage 🚮
๐Ÿ‘๏ธ0
Biotech_Tradez Biotech_Tradez 3 weeks ago
BUYER BEWARE: 71.7 Million shares added in last 30 days.

New OS is 468.5 million shares as of December 6, that is compared to 396.8 million shares on November 8. Since the stock closed at an all time low of $0.0006 on multiple days, these conversions might be at $0.0003 per share based on past conversions at 50% discount. This stock will end up at par value pretty soon which means the stock is worthless and the only real stakeholders are the debt holders.
๐Ÿ‘๏ธ0
John_Vallay John_Vallay 4 weeks ago
They claim to be doing a REORGANIZATION

They will make those claims using those types of words for as long as possible before filing bankruptcy. Except when they file bankruptcy it will have no reorganization plan in place. They will do so because of they can convert some of their debt to equity Collier can put more money in his pocket.

Their quarterly report that was filed on Nov 13 shows their bank account overdrawn $330.
They owe $26.2 million.

It also shows Alan Collier has raised $44 million which tells me that he has lived a very expensive lifestyle while shareholders have lost money since day 1 and continue to lose money because unfortunately most investors don't know any better.

If there are people on this board posting positive things about Collier, Endonovo, the stock or even the product I would ask them to reply to this message board by picking a place in NYC that we can meet for 15 minutes. You can make it a public space. I just want the opportunity to see and speak to the person or people that are dullards in their belief of anything positive about this entire situation.
👍 1
Craig305 Craig305 4 weeks ago
Strange how the day before the PR was released, there was high volume trading activity.
Then the day the PR is released, there was no volume or reaction to the news by the general public. 🤨
๐Ÿ‘๏ธ0
Cornerstone_Marketing Cornerstone_Marketing 4 weeks ago
https://x.com/endonovoinc/status/1865030447333544362?s=46&t=ZV-JoM4olm35bFSad3ozrw
๐Ÿ‘๏ธ0
Biotech_Tradez Biotech_Tradez 1 month ago
LOL. Using the AI buzzword to pump the stock!

These idiots haven't done anything in 2 years. They have no sales and no money to do anything so how exactly are they to build anything?

They have been putting out PR's for over two years and have done nothing they said in any of those bullshit PRs. In fact, they are in a worse condition having been delisted to the pink sheets and having their bank account overdrawn.

The reality is that this is a pump and dump PR to support the tens of millions of shares that are being converted at near par value. It is also Colliers only way to keep stealing from shareholders and not have to go out and get a job!
๐Ÿ‘๏ธ0
Cornerstone_Marketing Cornerstone_Marketing 1 month ago
https://x.com/jeff_lien/status/1864662260498747654?s=46&t=ZV-JoM4olm35bFSad3ozrw
๐Ÿ‘๏ธ0
Craig305 Craig305 1 month ago
Endonovo Restructures Business as Developers of Integrated AI Digital Health and Wellness Platform

LOS ANGELES, CA, UNITED STATES, December 4, 2024 /EINPresswire.com/ -- Endonovo Restructures Business as Developers of Integrated AI Digital Health and Wellness Platform

Endonovo Therapeutics, Inc. (OTCPK: ENDV) announced today that it has implemented a reorganization of business focusing on the development of a comprehensive digital healthcare and wellness platform with integration of artificial intelligence (AI) technologies. AI integrated services and technology will streamline access for healthcare providers, enhance patient engagement and expand retail sales of wellness and medical products to capitalize on and grow within the expanding digital health and wellness markets.

Development of Endonovo Digital Wellness Market Place

The company looks to expand its operations and enter the Wellness Industry to market wellness and medical products. In 2024, the wellness market is valued as a $4.3 trillion dollar industry that is expected to expand to $7 trillion dollars by 2025, as reported by statisa.com. ENDVโ€™s wellness platform will feature wellness and medical products and services, including its non-medical Pulsed Electro Magnetic Field (PEMF) multi-coil technology, on an AI integrated e-commerce platform/marketplace with distribution through network platforms.

Alan Collier, CEO of Endonovo Therapeutics, commented on the launch: "We are thrilled to be developing a digital healthcare and wellness platform with AI integration. Moving forward, our company mission will be to transform and improve patient care in all areas of the medical and wellness industries. Our proprietary digital health and wellness platform will help companies engage directly with retail customers, patients and healthcare providers.

Digital Health Care Market Opportunities

The digital health market size was valued at USD $375.99 billion in 2022 and is projected to grow to USD $452.79 billion in 2023 to USD 1,965.30 billion by 2030, exhibiting a CAGR of 23.3% during 2023-2030. North America dominated the global market with a share of 40.79% in 2022: reports Fortunebusinessinsites.com.

AI Integration Helps to Set ENDV Digital Platform Apart from Others

ENDV digital health and wellness systems AI integration will extend into marketing automation, where predictive analytics can refine targeted digital campaigns. This ensures that promotional materials resonate more effectively with specific patient demographics and healthcare providers, resulting in better engagement and return on investment (ROI).

Utilization of advanced analytics and AI will help users gain deep, actionable insights into customer behavior, preferences, and market trends. This data-centric approach will guide decision-making, product development, and marketing strategies.

These innovations will handle common inquiries, troubleshoot issues, and guide users through product information, thereby improving customer satisfaction and reducing support load on human agents. Our AI systems will continuously gather feedback and identify areas for improvement.

About Endonovo Therapeutics, Inc.

Endonovo Therapeutics is structured into two divisions: a Digital Health and Wellness Platform and a Legacy Division.

Digital Health and Wellness Platform: A Health and Wellness digital platform and e-commerce marketplace with AI integrated services and technology to streamline access for healthcare providers, enhance patient and retail customers engagement to capitalize and grow within the expanding digital health and wellness markets.
Legacy Division: as a commercial-stage developer primarily of noninvasive non-medical wearable Electroceuticals® therapeutic devices for general wellness
๐Ÿ‘๏ธ0
John_Vallay John_Vallay 1 month ago
Cornerstone Marketing
Based on your post it is safe to say you have zero knowledge of investing or you are a dullard.
👍 1
Biotech_Tradez Biotech_Tradez 1 month ago
$0 sales last quarter. What does that tell you?

That clown posts links to a twitter post like it means anything anymore. ENDV is a penny stock scam.
๐Ÿ‘๏ธ0
Craig305 Craig305 1 month ago
When is ENDV going to release a PR about their spinoff and Telehealth status? They have missed their targeted timelines.
๐Ÿ‘๏ธ0
Cornerstone_Marketing Cornerstone_Marketing 1 month ago
https://x.com/endonovoinc/status/1863582542378770560?s=46&t=ZV-JoM4olm35bFSad3ozrw
๐Ÿ‘๏ธ0
retired early retired early 1 month ago
Yes all $48 bucks worth. Oh that poor nude mouse.
๐Ÿ‘๏ธ0
Craig305 Craig305 1 month ago
Strange that ENDV is showing some volume before market open. 🤨
๐Ÿ‘๏ธ0
brojazzy brojazzy 1 month ago
This isn't a company, this is a scam
๐Ÿ‘๏ธ0
Biotech_Tradez Biotech_Tradez 1 month ago
I called you out for being a Paid Cheerleader and you denied it, while having received 3,500,000 shares of stock.

I also called you out for spreading lies and misinforming people about this contraption. Among the lies is that the device works and is "FDA Approved." This device is FDA Cleared not Approved and in recent studies it, specifically the Rhodes study, was basically the same as a placebo.

This device has not been shown to be effective in large human studies and was cleared by the FDA based on a resubmitted 510(k) arguing that the device was "substantial equivalent" to a device that was already legally marketed before the FDA started regulating medical devices.

You are either ignorant and severely misinformed or you are spreading lies. I have on numerous occasions stated that this device is not FDA Approved yet you keep spreading the lie that it is despite the evidence to the contrary. If the contraption were FDA approved then it would have the clinical trials to show its effectiveness and it would have sales.

The main difference between FDA clearance and FDA approval is the level of regulatory scrutiny and the types of evidence required:

FDA approval
A higher standard that involves extensive research, clinical trials, and documentation of safety, efficacy, and manufacturing processes. The FDA decides that the benefits of the product outweigh the known risks.

FDA clearance
A lower standard that involves demonstrating that the product is "substantially equivalent" to another similar legally marketed device that has already been approved. Specific testing on FDA cleared products may be absent or minimal.

The FDA uses two distinct regulatory procedures for approval and clearance:

FDA-approved
Manufacturers must submit a Premarket Approval (PMA) application that contains results from clinical investigations.

FDA-cleared
Manufacturers can submit a Premarket Notification (also called a 510(k)) to the FDA.
๐Ÿ‘๏ธ0
Cornerstone_Marketing Cornerstone_Marketing 1 month ago
Zero point in talking with you. This clearly wasn't investment advice in any manner. It was said to "support the relaunch of the device and get it to people it helps" i did and do stand by this statement. In fact I say it again- this device WORKS it is approved by the fda and has recent clinical studies showing it has many other uses as well. It is in use in multiple VA facilities and the company is still in the process of selling this to Ira and a new company which if completed is great for the device and shareholders. 
I am a loyal supporter of this device and company and not being compensated by ENDV in any manner. 
 I think more will be made clear on the device and ENDV's future at some point in the future. Until then I remain a supporter.
๐Ÿ‘๏ธ0
Biotech_Tradez Biotech_Tradez 1 month ago
Funny that the account you use to post your "opinions" is also the name of the company that was paid 3,500,000 shares.

Your own words on January 13, 2023 Post # 32689:

With so much coming from the company the bears are in full scramble mode to bash this ticker now. Since they canโ€™t say the product doesnโ€™t work and the new management coming on in Mr Kann and Ira are both highly respected in their fields itโ€™s seems important to build a false rhetoric around what caused the previous launch to fail so they can hold this down longer.

Itโ€™s in the best interest of all past and future shareholders as well as the community at larger to support the relaunch of this product, get it to the people who it can HELP and return value to shareholders.

Thank you

Giving investment advice while taking shares from the company without disclosing that fact is likely illegal. You are either brazen, dumb or have a really bad attorney.
๐Ÿ‘๏ธ0
Cornerstone_Marketing Cornerstone_Marketing 1 month ago
All my posts are my own opinion- it's in my socials bio

If you actually followed my account I post about hundreds of different stocks almost none of which we have ever had any contact with because this is a personal account and I invest widely and never buy or sell any shares of a company the company has a contract with.
  I'm still here little buddy still talking ENDV still not compensated nor ever compensated for posting.

Sofpulse and ENDV I still believe have a big future.

 

๐Ÿ‘๏ธ0
Biotech_Tradez Biotech_Tradez 1 month ago
No, Jeff Lien, aka PennyStockSnipers, aka Cornerstone Marketing is a penny stock promoter that shows up on penny stock boards, Discord and other platforms to pump stocks he is compensated for without disclosing that fact.

You showed up here in December of 2022 as PennyStockSnipers to pump this stock when it was trading sub penny and had very little volume. You not only probably bought shares sub penny before you started pumping the stock, but you also received 3,500,000 shares of common stock on 1/03/23. Convenient how you didn't mention that fact in your little DD package. In fact you outright denied it numerous times when you were called out for it. You can call yourself whatever you want but the truth is you pumped this stock.

Your own words on December 14, 2022 - Post # 32627

Funny how the bears run away as this continues to shine. Company is starting to slowly come out of a forced closure due to the pandemic. Letโ€™s see what they have plannedโ€ฆ I bet itโ€™s HUGE based on what weโ€™ve seen so far. Headed back to NASDAQ

Does that sound like social media management to anyone, or more like pumping a stock? When the pumpers call you a bear it is a clear sign they have no argument at all. Not only did everything I said come true including calling you out when you first showed up as a penny stock pumper, but this company did not go "back to NASDAQ" because it never was on it, it went even further down losing people 90% or more of their investment, none of their sales plans panned out and they were delisted from the OTCQB down to the pink sheets and based on their quarterly report, they generated $0 sales last quarter.

Do everyone a favor and leave, permanently this time. I would not be surprised if the SEC comes knocking at your door or a lawsuit comes your way given your cavalier attitude and brazen stock promotion.
๐Ÿ‘๏ธ0
Cornerstone_Marketing Cornerstone_Marketing 1 month ago
Cornerstone Marketing is a website and social media management company. 
We are NOT paid to promote stocks from our personal/company accounts in any manner. Our contracts are specific to management of company accounts and/or introduction to actual influencers who would then have to disclose payment for promotion.
 We do NOT have any contract with ENDV nor have had for almost a year but still post about them.
Why? Same reason we posted from our account in the past. We like the company and the asset Sofpulse. 
Everyone is entitled to his or her personal opinion and my posts reflect that. 
Clearly you are bearish and that's fine as well.
๐Ÿ‘๏ธ0
Cornerstone_Marketing Cornerstone_Marketing 1 month ago
https://x.com/endonovoinc/status/1859241459633074677?s=46&t=ZV-JoM4olm35bFSad3ozrw
๐Ÿ‘๏ธ0
Biotech_Tradez Biotech_Tradez 1 month ago
BUYER BEWARE: Jeff Lien aka Cornerstone Marketing is a paid stock promoter that doesn't disclose he is getting paid by the companies he is promoting.

ENDV granted Jeff Lien of Cornerstone Marketing, aka PennyStockSnipers, 3,500,000 shares of common stock on 1/03/23 just before he magically appeared on this and other penny stock boards promoting the stock. A fact that Jeff Lien never disclosed when promoting the stock, which may be illegal. Anyone that bought on the advice of Jeff Lien, aka Cornerstone Marketing, aka PennyStockSnipers and lost money should look to sue him and report him to the SEC.

Craig Please post this as a sticky. Potential investors must be aware of who this person is and what his motivation is behind pushing this stock.
๐Ÿ‘๏ธ0
Cornerstone_Marketing Cornerstone_Marketing 1 month ago
https://x.com/endonovoinc/status/1859241459633074677?s=46&t=ZV-JoM4olm35bFSad3ozrw
๐Ÿ‘๏ธ0
brojazzy brojazzy 2 months ago
lmfao what a complete and utter scam, has been since day 1
๐Ÿ‘๏ธ0
Biotech_Tradez Biotech_Tradez 2 months ago
BUYER BEWARE: New ENDV Target Stock Price is $0.0004 See Below:

On June 11, 2024 ENDV issued 19,807,975 shares of common stock at a price of $0.0004 to Trillium Partners, LP for the conversion of $7,923 in debt. The closing stock price on 6/11/24 was $0.0008 per share, thus the conversion was at a 50% discount to the closing price.

This conversion was preceded by the issuance of 25,875,613 shares of common stock at a price of $0.0008 to Trillium Partners, LP for the conversion of $20,700 in debt. The conversion was done on 5/15/24 when the closing price of the common stock was $0.0016 per share, thus the conversion was at a 50% discount to the closing price. Since that conversion the price has been driven down 50% to the price of the conversion at $0.0008 per share.

Therefore the volume that has been generated has been through the selling of the highly discounted conversion shares into the market. This means that the stock price will be driven down as long as they can get $0.0004 per share. An informed investor would thus not buy below the conversion price since there is a shareholder with a lower cost basis that is motivated to sell shares.

These conversions are being outlined in the quarterly reports submitted to the SEC. The good thing about these idiots being delisted from the OTCQB down to the pink sheets is that they now have to disclose their stock issuances, broken down in detail including the date, number of shares, the name of the person being issued shares and the price at which the shares are issued.

This has not only revealed the conversion of debt at steep discounts but also highlighted that Alan Collier, the CEO and sole Board Member has gifted himself over 45 million shares via his consulting firm Blue Ridge Consulting. This is of course a reward for diluting all of his investors following a 1-for-1,000 reverse split followed by the issuance of over 350,000,000 shares resulting in investors losing over 99.99% of their investments. So while his investors were completely wiped out, Alan Collier increased his ownership stake in ENDV.

Furthermore, upon a more detailed review, the quarterly report also states that ENDV granted Jeff Lien of Cornerstone Marketing, aka PennyStockSnipers, 3,500,000 shares of common stock on 1/03/23 just before he magically appeared on this and other penny stock boards promoting the stock. A fact that Jeff Lien never disclosed when promoting the stock, which may be illegal. Anyone that bought on the advice of Jeff Lien, aka Cornerstone Marketing, aka PennyStockSnipers and lost money should look to sue him and report him to the SEC.

Craig, please highlight this post as a sticky, it is too important for potential new investors to be informed of what they are getting themselves into. If they read this and decide to still buy then that is on them, after all these penny stocks are Caveat Emptor.
๐Ÿ‘๏ธ0
Craig305 Craig305 2 months ago
Good catch. I assumed it was a true quarterly ER and did not notice it was YTD.

I also noticed a "consultant" has a lawsuit against ENDV for non payment. I tried searching for who it can be and cannot find anything about it. 
๐Ÿ‘๏ธ0
Biotech_Tradez Biotech_Tradez 2 months ago
They had ZERO revenue in Q3 and Negative $330 in Cash.

The numbers are for the nine months ending September 30. If you compare the numbers from the last report they are the same for both revenue and COGS.

Period ending 6/30 Revenue: $10,043 and COGS: $6,709 Gross Profit: $3,335

Period ending 9/30 Revenue: $10,043 and COGS: $6,709 Gross Profit: $3,335 EXACTLY THE SAME NUMBERS WHIICH MEANS NO REVENUE! They did not sell a single contraption in the last 3 months.

ENDV has virtually no assets and nearly $20 million in very real liabilities. Furthermore, their contraption has not been shown to be effective in large double-blind randomized and controlled clinical trials necessary to receive reimbursement and/or justify the cost in surgery.

It has been two years since they announced their proposed spin off yet no real progress has been made. My guess is that their new guy Ira cannot get the financing to take this POS into a NASDAQ company. This company's only avenue is bankruptcy court to rid itself or fundamentally restructure its debt. The company cannot repay $7 million in debt along with another $5.6 million in accrued interest no matter what financing scheme they purport to have brewed up. It is difficult to see what value they got for $7 million in debt they put on the company besides Collier paying himself and his cronies bloated salaries. You could build a very successful company with that amount and yet these idiots have only every driven down the value of the company and its assets.
๐Ÿ‘๏ธ0